These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Hammarsten J; Högstedt B Blood Press; 1999; 8(1):29-36. PubMed ID: 10412880 [TBL] [Abstract][Full Text] [Related]
4. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Hammarsten J; Högstedt B Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the clinical parameters of benign prostate hyperplasia in diabetic and non diabetic patients. Ozcan L; Besiroglu H; Dursun M; Polat EC; Otunctemur A; Ozbek E Arch Ital Urol Androl; 2017 Mar; 89(1):26-30. PubMed ID: 28403591 [TBL] [Abstract][Full Text] [Related]
6. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Hammarsten J; Högstedt B Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674 [TBL] [Abstract][Full Text] [Related]
7. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia. Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592 [TBL] [Abstract][Full Text] [Related]
8. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Roehrborn CG; Boyle P; Gould AL; Waldstreicher J Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388 [TBL] [Abstract][Full Text] [Related]
9. Visceral adiposity index is associated with benign prostatic enlargement in non-diabetic patients: a cross-sectional study. Besiroglu H; Ozbek E; Dursun M; Otunctemur A Aging Male; 2018 Mar; 21(1):40-47. PubMed ID: 28823197 [TBL] [Abstract][Full Text] [Related]
10. [Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen]. Li F; Yin X; Li D; Yin Z; Qi S; Shi H; Gao J; Zhang X Nan Fang Yi Ke Da Xue Xue Bao; 2015 Dec; 35(12):1721-4. PubMed ID: 26714904 [TBL] [Abstract][Full Text] [Related]
11. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA. Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951 [TBL] [Abstract][Full Text] [Related]
12. [Ultrasound indicators of the prostate, urinary bladder and uroflowmetry parameters in the diagnosis of infravesical obstruction in men with benign prostatic hyperplasia]. Krivoborodov GG; Efremov NS; Bolotov AD Urologiia; 2017 Oct; (5):9-14. PubMed ID: 29135135 [TBL] [Abstract][Full Text] [Related]
13. Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia. Kim JM; Song PH; Kim HT; Moon KH Korean J Urol; 2011 Jun; 52(6):401-5. PubMed ID: 21750751 [TBL] [Abstract][Full Text] [Related]
14. Benign prostate hyperplasia: average volume in southwestern Nigerians and correlation with anthropometrics. Badmus TA; Asaleye CM; Badmus SA; Takure AO; Ibrahim MH; Arowolo OA Niger Postgrad Med J; 2012 Mar; 19(1):15-8. PubMed ID: 22430596 [TBL] [Abstract][Full Text] [Related]
15. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341 [TBL] [Abstract][Full Text] [Related]
16. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666 [TBL] [Abstract][Full Text] [Related]
17. The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients:a cross-sectional study. Besiroglu H; Dursun M; Otunctemur A; Ozbek E Aging Male; 2017 Sep; 20(3):198-204. PubMed ID: 28332908 [TBL] [Abstract][Full Text] [Related]
18. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer. Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963 [TBL] [Abstract][Full Text] [Related]
20. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison. Geavlete B; Stanescu F; Iacoboaie C; Geavlete P BJU Int; 2013 May; 111(5):793-803. PubMed ID: 23469933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]